Introduction to management issues in COPD
=========================================

According to the World Health Organization (WHO) estimates, currently 210 million people have COPD and 3 million people died of COPD in 2005. The WHO predicts that COPD will become the fourth leading cause of death worldwide by 2030 ([@b19-copd-3-371]). The burden of COPD assessed by disability-adjusted life years (DALYs) ranks 10th worldwide ([@b105-copd-3-371]). Total deaths from COPD are projected to increase by more than 30% in the next 10 years unless urgent preventive measures are in place ([@b19-copd-3-371]).

Although COPD cannot be cured, optimal management provides symptom control, slows progression of the disease, and may improve the quality of life ([@b49-copd-3-371]; [@b79-copd-3-371]). Management of COPD becomes suboptimal when physicians fail to prescribe appropriate therapies, due to poor adherence to evidence-based guidelines and underdiagnosis ([@b87-copd-3-371]; Foster et al 2007), or when patients fail to adhere to prescribed treatment regimens. There are a limited number of studies on the physician knowledge and practice patterns for individuals with COPD that may result in suboptimal management and adversely affect patient outcomes ([@b74-copd-3-371]; [@b34-copd-3-371]; Foster et al 2007; Sestini et al 2007).

Adherence is defined as "the extent to which a person's behavior (in terms of taking medications, following diets, or executing lifestyle changes) coincides with medical or health advice" ([@b43-copd-3-371]). Adherence to medication regimens is often suboptimal when patients are on long-term pharmacotherapy using repeat prescriptions. A study published by the WHO estimated 50% adherence or less for patients on long-term pharmacotherapy ([@b104-copd-3-371]).

Adhering to inhaled medications is of paramount importance in the management of patients with COPD in both clinical and ambulatory settings. These pharmacologic agents include bronchodilators and corticosteroids used in a variety of aerosol devices that include small volume nebulizers (SVNs), pressurized metered-dose inhalers (pMDIs), and dry powder inhalers (DPIs). Selection of the medication and the device typically depends on the efficacy of the different inhaled medications and the devices. However, this selection is often limited by the availability of a match between the medication prescribed and the aerosol device. While it is desirable that the medications prescribed to a patient are delivered through the same or similar devices, adherence to the right medication -- device combination may be influenced by commercial availability. The medication -- device availability problem will be compounded by the phasing-out of CFC-propelled pMDIs at the end of 2009 as proposed by the Federal register ruling ([@b16-copd-3-371]). Replacement of CFC-propelled pMDIs by hydrofluoroalkane (HFA)-propelled pMDIs has been more difficult than expected since it has resulted in a redesign of the entire pMDI metering-valve system at a higher cost than simply replacing the propellant. This transitioning will initially restrict the list of available agents and could have considerable financial implications in the routine management of patients with COPD ([@b77-copd-3-371]; [@b86-copd-3-371]).

Medication regimens for patients with COPD are particularly vulnerable to adherence problems because of the chronic nature of the disease, the use of multiple medications or polypharmacy, and the periods of symptom remission. Patients with COPD are often prescribed aerosolized medications to use from 2 to 6 times daily plus concurrent therapy for other comorbidities that may include diabetes, hypertension, and coronary artery disease ([@b53-copd-3-371]; [@b88-copd-3-371]).

Despite the efforts of the global initiative for chronic obstructive lung disease (GOLD) to provide clinicians with the best therapeutic guidance, adherence to pharmacologic therapy among patients with COPD has been historically poor ([@b102-copd-3-371]; [@b50-copd-3-371]; [@b29-copd-3-371]; [@b34-copd-3-371]; [@b54-copd-3-371], [@b52-copd-3-371]). Patients with COPD display significantly lower adherence to treatment than asthmatic patients ([@b45-copd-3-371]; [@b21-copd-3-371]; [@b40-copd-3-371]). Several studies have reported that an average of 60% of patients with COPD do not adhere to prescribed therapy ([@b20-copd-3-371]; [@b93-copd-3-371]; [@b31-copd-3-371]; [@b8-copd-3-371]; [@b54-copd-3-371], [@b52-copd-3-371]; [@b40-copd-3-371]) and that up to 85% of patients use their inhaler ineffectively ([@b22-copd-3-371]; [@b94-copd-3-371]; [@b96-copd-3-371]; [@b99-copd-3-371], [@b101-copd-3-371]; [@b44-copd-3-371]; [@b82-copd-3-371]). British and Swedish studies indicate that 10%--20% of repeat prescriptions never reach a pharmacy ([@b76-copd-3-371]; [@b70-copd-3-371]).

Adherence to therapy in COPD is complex. Patients with COPD require adequate education on the disease process, comorbidities, and also on the use of different medications and devices ([@b20-copd-3-371]; [@b29-copd-3-371]). They often need to make important behavioral and lifestyle changes such as starting a smoking cessation program, adhering to an exercise program, and wearing oxygen.

Several methods are used to measure adherence: refill adherence based on pharmacy records of dispensed prescription or manual recording of collected prescriptions, and self-reports of compliance using medication adherence report scales (MARS) ([@b34-copd-3-371]). Although adherence should ideally be measured upon ingestion or administration of the medication, this is not practical for large groups. Most studies rely on a mixture of refill adherence and self-report. Since the most commonly used method to measure is the self-report ([@b32-copd-3-371]) this review focuses only on this technique.

Numerous factors predispose patients with COPD to poor adherence. Recognition of the type of nonadherence in patients with COPD must be the first step in this complicated process of improving adherence. Prescription of an inhaled medication requires knowledge of different groups of medications and the potential clinical efficacy of combinations. It also requires being familiar with several aerosol delivery devices. Newer medications and devices improve clinical outcomes and ease of use but typically mean a higher out-of-pocket expense for patients. Patient's perceptions of their illness, their understanding of the treatment, and their relationship with the primary care provider are critical to adherence to therapy. It is the aim of this manuscript is to review some of these important aspects affecting adherence to medication and to identify some predictors of poor adherence in patients with COPD.

Underuse, overuse, and improper use
===================================

There are three classic types of nonadherence to therapy: underuse, overuse, and improper use. Underuse is defined as a reduction of the apparent daily use versus a standard dose of a medication that is indicated for the treatment or prevention of a disease or condition ([@b58-copd-3-371]; [@b39-copd-3-371]). Improper use or inappropriate use is confirmed by determining whether a drug is ineffective, not indicated, or if there is unnecessary duplication of therapy ([@b88-copd-3-371]).

Although these three factors have been well defined in the literature, there is limited evidence that links specific factors to each form of nonadherence in patients with COPD. The most common type of nonadherence in patients with COPD is underuse ([@b39-copd-3-371]; [@b34-copd-3-371]). By contrast, improper use is the most frequent type of nonadherence in patients older than 65 years with polypharmacy (taking 2 or more medications) ([@b88-copd-3-371]). Factors with tendency for association with unnecessary drug use include white race, income \<US\$30,000/year, more than 6.8 (±2) of prescription medications, and lack of patient's health belief (Rossi et al 2007). In older adults, higher levels of independence and self-reliance have been associated with lower adherence to a medication regimen ([@b46-copd-3-371]). The two most common reasons for a medication to be considered inappropriate are lack of effectiveness and lack of indication ([@b41-copd-3-371]; [@b88-copd-3-371]; Rossi et al 2007). Inhaled medications are not on the top 5 medications that are inappropriately used in patients older than 65 years ([@b41-copd-3-371]; Rossi et al 2007).

In patients with COPD, underuse is followed in frequency by overuse and improper use of the medication delivering device. Underuse could be sporadic or systematic. From forgetting an occasional dose to changing dosing schedule, patients with underuse are at a higher risk for adherence-related morbidity. A recent evaluation of the use of ICS in primary care patients revealed that up to 30% of the patients did not have a clear indication for this medication ([@b59-copd-3-371]). Although improper use and underuse often coexist in the same patient, improper use may not correlate with underuse ([@b88-copd-3-371]).

There is evidence of overuse of short-acting beta agonists in patients with asthma (Lynd et al 2002), but little is known about the real incidence of overuse in patients with COPD. During respiratory distress, approximately half of the patients report using more than the prescribed amount of medications ([@b29-copd-3-371]; [@b8-copd-3-371]).

Clinical efficacy of major classes of medications and combinations
==================================================================

Determination of clinical efficacy involves evaluation of outcomes such as lung function, rate of exacerbations, and mortality. However, these outcome parameters need to be a reflection of the clinical efficacy perceived by the patient. A combination of objective and subjective clinical efficacy is a critical determinant of adherence to therapy. Inhaled corticosteroids (ICS), long-acting β~2~-agonists (LABAs), and anticholinergics have been recommended for the treatment of COPD. LABAs are recommended by GOLD (GOLD 2007) when patients continue to experience problems on short-acting bronchodilators (SABAs). The most obvious benefit of combination therapy is in terms of patient convenience that may lead to greater treatment adherence.

Lung function
-------------

Current evidence indicates that there is statistically significant difference in FEV~1~ and in health status measurements in favor of LABAs ([@b3-copd-3-371]) and ICS ([@b106-copd-3-371]). Several randomized controlled trials have found that a LABA -- ICS combination therapy is associated with a significant increase over the baseline FEV~1~ when compared with the groups receiving placebo, LABA alone, or ICS alone ([@b12-copd-3-371]; [@b67-copd-3-371]). Addition of tiotropium to the LABA -- ICS combination significantly improves lung function ([@b1-copd-3-371]). The combination of ipratropium bromide and albuterol in patients with COPD results in significant improvement in peak FEV~1~ compared with albuterol or ipratropium alone ([@b36-copd-3-371]). [@b92-copd-3-371] reported no significant difference in lung function measured by FEV~1~ in a group of patients with COPD randomized to SVN, pMDI, and concomitant treatment involving SVN (morning and night) plus pMDI (afternoon and evening) using a combination of albuterol and ipratropium bromide.

Rate of exacerbations, hospitalizations, and mortality
------------------------------------------------------

Using LABA -- ICS is associated with a significant reduction in the rate of exacerbation, admission rates, and mortality ([@b1-copd-3-371]; [@b12-copd-3-371]; [@b68-copd-3-371], [@b69-copd-3-371]). Combination therapy may reduce 1 exacerbation of COPD every 2--4 years ([@b12-copd-3-371]). Patients with COPD at any stage may perceive the lower health resource utilization as a motivator to adhere more rigorously to medications. However, this correlation has not been determined. Trials of short-acting anticholinergic and SABA combinations have shown a significant reduction in exacerbations compared with monotherapy, but no difference in mortality ([@b84-copd-3-371]).

Use of rescue medication
------------------------

The use of rescue medications during COPD exacerbations may seem to be the most feasible explanation for overuse. During an exacerbation, an average of 1 additional puff during the day and half a puff during the night is seen two weeks prior and after an exacerbation regardless of COPD stage ([@b14-copd-3-371]). However, changes in rescue medication intake poorly correlate with exacerbations ([@b14-copd-3-371]). The use of LABA -- ICS has been associated with a significant reduction in mean puffs per day of SABA ([@b61-copd-3-371]; [@b37-copd-3-371]), significant increases in the percentage of nights with no awakenings requiring SABA versus placebo, and a significant difference in median percentage of days without use of relief medication ([@b13-copd-3-371], [@b15-copd-3-371]; [@b91-copd-3-371]).

Safety and tolerability of major classes of medications and combinations
========================================================================

Adverse events to medications are reported by 90% of the patients with COPD ([@b12-copd-3-371]). The presence of serious side effects negatively affects adherence. An increase in the risk of pneumonia in patients with COPD using a combination of ICS and LABA has been reported in several studies ([@b12-copd-3-371]; [@b68-copd-3-371]). The most frequently reported adverse event was an exacerbation of COPD. Although there is no significant difference in the occurrence of overall reported adverse events between LABA -- ICS and placebo, pneumonia, candidiasis, nasopharyngitis, hoarseness, and upper respiratory tract infections (URTI) occurred more frequently when treated with a LABA -- ICS combination ([Table 1](#t1-copd-3-371){ref-type="table"}) ([@b67-copd-3-371]).

Adherence to individual medications and combinations
====================================================

Type of medication
------------------

Patients with COPD have the lowest adherence to a regimen that included inhaled anticholinergic agents followed in order by the inhaled sympathomimetics, theophylline, corticosteroids, and antibiotics ([@b29-copd-3-371]) ([Figure 1](#f1-copd-3-371){ref-type="fig"}).

The ability to produce quick relief of symptoms or the safety profiles could explain class differences. It has been suggested that compliance to corticosteroids should be lower than to bronchodilators, because of the lack of direct symptom-relieving effect of the corticosteroids. However, patients may adhere to regimens that include oral corticosteroids and antibiotics more frequently because these medications are typically prescribed for short periods of time. Since they are prescribed to deal with acute symptoms, the patients' perception is that these medications are more urgent and necessary.

Complexity of medication regimens
---------------------------------

It has been previously reported that overall, the average number of time-contingent and as needed (P.R.N.) medications per patient may be as high as 6.26 (range, 1--16) ([@b29-copd-3-371]). Up to 77% of patients with COPD may receive 2 or more oral-contingent medications ([@b29-copd-3-371]). One-third typically receive 2 or more inhaled time-contingent medications, 45% receive 1 inhaled time-contingent medication, and 23% receive no inhaled time-contingent medications ([@b29-copd-3-371]). The average of prescribed oral time-contingent and inhaled time-contingent medications are 3.53 and 1.17, respectively. Thirty percent of patients with COPD are prescribed oral P.R.N. medications and 17% had inhaled P.R.N. medications ([@b29-copd-3-371]). Many of these medications have different dosing schedules. Thus, it is quite common for patients to be prescribed a combination of 5--8 oral and inhaled medications, with many medications requiring different dosing patterns.

Use of ipratropium bromide and albuterol in one inhaler is associated with a significantly lower risk of an emergency department visit or hospitalization, lower mean monthly health charges, shorter hospital stays, and greater likelihood of compliance than if used in two separate inhalers ([@b18-copd-3-371]).

Selection of the aerosol delivery device
========================================

All aerosol delivery devices have relative advantages and disadvantages, as well as a potential to affect outcomes. The marketing of a myriad of aerosol delivery devices has resulted in a confusing number of choices for clinicians and patients. Although the fundamental principle of prescribing is based on the use of the most clinical and cost-effective medication and device, choices may become influenced by factors that are not clinically relevant or evidence-based. The ability of the patient to use the prescribed device affects adherence to treatment.

Clinical efficacy
-----------------

The overall conclusion of numerous studies demonstrates that there is no evidence to support clinically important differences between aerosol devices. A systematic review ([@b30-copd-3-371]) identified 394 randomized controlled trials (RCTs) assessing inhaled corticosteroid, β~2~-agonist, and anticholinergic agents that were delivered by pMDI, pMDI with spacer/holding chamber, nebulizer, or DPI. None of the pooled meta-analyses found a significant difference between devices in any efficacy outcome of patients with asthma and COPD in the outpatient and hospital acute care settings. A recent clinical trial ([@b92-copd-3-371]) reported no appreciable changes from baseline or pair wise differences between SVN and pMDI treatment arms at weeks 6 or 12 in peak flow measurements and symptom scores of patients with COPD.

In all the pooled meta-analyses, each of the delivery devices has provided similar outcomes in patients using the correct technique for inhalation. However, clinical benefit also depends on the ability of the patients to use the device and on their adherence. Real-life observational studies that evaluated patient inhalation techniques have shown frequent improper use of pMDIs and DPIs that may result in significant clinical differences between devices.

Patient acceptability and preference
------------------------------------

Elderly patients with COPD show a preference for the SVN with regard to effectiveness and in favor of the pMDI with regard to acceptability ([@b4-copd-3-371]). SVN treatment is often prescribed to patients who prefer SVNs or demonstrate poor coordination with either a pMDI or DPI. Because SVNs are not as portable as pMDIs or DPIs, ambulatory patients find pMDIs and DPIs more convenient for use when they are away from home.

Inhalers and dosing technique
=============================

Although patients may adhere to the dosing schedule, they may use the inhaler improperly ([@b63-copd-3-371]). Inhaler specific design features also contribute significantly to the patient's adherence to treatment ([@b11-copd-3-371]; [@b103-copd-3-371]; [@b98-copd-3-371]). Patient technique is a process that encompasses an individual's previous experiences, education, abilities, and the teaching received on the specific device. These factors may interact to various degrees with the different types of inhaler devices to influence eventual technique and adherence. The typical method to evaluate inhaler technique is by assigning a score on the number of steps performed correctly out of the total number of possible steps. An evaluation of inhaler use in 316 patients suffering from asthma or COPD found that 89% of the patients made at least one mistake in the inhalation technique ([@b96-copd-3-371]). The most common skill error was "not continuing to inhale slowly after actuation of the inhaler" (69.6%). The nonskill item most patients had difficulties with was "exhaling before the inhalation" (65.8%). Patients who used a pMDI made significantly fewer nonskill mistakes than patients using a DPI ([@b96-copd-3-371]). A systematic review ([@b10-copd-3-371]) using the outcome of "ideal" inhaler technique showed that the percentage of patients with all steps correct was 43% for pMDI alone, 55% for pMDI + spacer, and 59% for DPI. There was statistical difference between pMDI alone and DPI or pMDI + spacer, but whether this is clinically significant is difficult to judge, particularly if cost efficacy is considered. The data support the conclusion of many reports that pMDI devices are poorly used.

When the pMDI is used, more than 50% of subjects may perform ≤5 out of 9 steps correctly and only about 11% of the subjects could perform all steps correctly ([@b60-copd-3-371]) (see [Table 2](#t2-copd-3-371){ref-type="table"}).

The most frequent problem is failure to coordinate actuation with inhalation and to hold their breath after inhalation. When patients are asked simple questions to establish if they have a basic understanding of their nebulized medication (eg, do you know what medications you use? how often? do you know if the medication you take has a bronchodilatory or anti-inflammatory effect?), 52% of patients are not able to answer these questions correctly; although 91% believe that they do understand the treatment they were prescribed. Of those who are unable to answer correctly, 60% are nonadherent ([@b7-copd-3-371]). To complicate matters, primary care physicians are not familiar with relevant features of currently available inhalers (Sestini et al 2007).

Patient preference -- ease of use
---------------------------------

In a recent comparison of the Diskus^®^ inhaler (DK) and the Handihaler^®^ (HH) regarding preference and ease of use, although there was no difference in the number of instructions needed for both inhalers, more patients preferred the DK. The most important general items for patients were hygiene and a clear instruction leaflet ([@b97-copd-3-371]). Of the inhaler-specific aspects, more than 90% of patients find ease of use in general, ability to take the medication quickly, ease of use during an exacerbation, the feel in the hand, and ease of the cap important or very important ([Figure 2](#f2-copd-3-371){ref-type="fig"}).

Inhaler resistance is a factor that contributes to suboptimal inhalation of medication in patients with COPD. Over the years, there has been a trend to increase inhaler resistance. Patients have a preference for devices that allow them to inhale the medication quickly ([@b97-copd-3-371]). Eight popular DPIs seem to be acceptable with regard to their internal resistance, but the trend to increase the resistance of inhalers may have reached a critical point with regard to acceptability ([@b97-copd-3-371]).

Patients report overwhelmingly (98% vs 2%) that perceived benefits from using a SVN over a pMDI or DPI (eg, improved breathing, greater self-confidence, and less need to contact health care providers) outweigh perceived disadvantages (eg, longer time required for nebulizer treatment and cleaning the device) ([@b6-copd-3-371]).

Pharmacoeconomics
=================

Pharmacoeconomics has emerged to formalize the decision-making process for the adoption of new medications and devices. In addition, the implementation of clinical practice guidelines can be costly ([@b42-copd-3-371]). In the US, in 2000, the total annual costs related to COPD were in excess of \$US32 billion ([@b19-copd-3-371]). In the US, 97% of people over 65 years who receive incomplete Medicare coverage need supplemental insurance ([@b78-copd-3-371]). Since the Medicare Prescription Drug Improvement and Modernization Act of 2003 only went into effect in 2006, its impact on suboptimal medication use is still to be determined ([@b62-copd-3-371]).

Medication-related cost
-----------------------

Although underuse can result in morbidity and health care cost, the cost of the medication is believed to be one of the most important determinants of underuse ([@b38-copd-3-371]; [@b89-copd-3-371]; [@b62-copd-3-371]). Tiotropium has demonstrated the highest expected net benefit for ratios of the willingness to pay per quality-adjusted life-year (QALY) ([@b81-copd-3-371]). The incremental cost per additional QALY is lower with tiotropium than salmeterol or ipratropium bromide ([@b71-copd-3-371]). The practice of offering tiotropium bromide for patients with COPD-related hospitalizations instead of ipratropium bromide is favored ([@b72-copd-3-371]). There is a potential overall cost saving of 83% after the addition of tiotropium to the medical regimen of patients with COPD ([@b55-copd-3-371]). Fluticasone -- salmeterol (FLU -- SAL) and budesonide -- formoterol (BUD -- FOR) are the most cost effective strategies. However, there is a slight superiority of FLU -- SAL. Incremental cost-effectiveness of FLU -- SAL versus SAL was 679.5 (US\$1,001) per avoided exacerbation and 3.3 (US\$4.86) per symptom-free day ([@b24-copd-3-371]).

Device-related cost
-------------------

Important breakthroughs in biotechnology and nanotechnology have resulted in the creation of a myriad of aerosol devices that have dramatically improved medication delivery to patients with respiratory diseases ([@b25-copd-3-371]; [@b26-copd-3-371]). However, these advances have come at a steep price. It is well known that the costs of both the DPIs and SVNs are substantially higher than pMDI devices for all classes of medication ([@b10-copd-3-371]), that there is lack of many DPIs in generic forms, and that while 80% of SVNs and medications are reimbursable by Medicare, pMDIs and DPIs are not covered ([@b77-copd-3-371]). Although spacers significantly improve drug delivery, the high cost of these simple attachments may be sufficient to deter many patients from using them. Although routine substitution of pMDI therapy for SVN therapy can be accomplished with considerable reductions in the hospital setting ([@b9-copd-3-371]), several authors have reported that no aerosol delivery device could be categorically rated as not cost-effective ([@b73-copd-3-371]).

Patient beliefs, experiences, and behaviors
===========================================

Significant differences in health beliefs, experiences, and behaviors are observed between COPD patients with different levels of adherence. While education plays an important role on modifying beliefs, patients are likely to modify the recommended therapy based on how they feel or their level of dyspnea.

COPD patients with suboptimal adherence have insufficient understanding about their illness and the options for managing their illness, show a low level of satisfaction with and faith in the treating physician, and rely more on natural remedies ([@b34-copd-3-371]). They also perceive the management of COPD as a mystery and show low confidence in drug therapy ([@b95-copd-3-371]; [@b45-copd-3-371]; [@b34-copd-3-371]).

The degree of difficulty to handle some medications and patient satisfaction with the information shared by the doctors is the more significant patient experiences that correlate with adherence to therapy for COPD ([@b34-copd-3-371]). The level of patient satisfaction heavily depends on the adequacy of communication between clinician and patient as perceived by the patient. Although complexity of medication regimens, concerns about side effects, cost of treatment, and the number of regular medications in the regimen have been considered critical to adherence, these experiences have not been consistently correlated with poor adherence by all the studies ([@b34-copd-3-371]).

Since patients with COPD are often coached to increase their prescribed doses when exacerbations are identified, the behavior of decreasing the doses when feeling well explains quite well the frequency of underuse in some patients with COPD. This change in frequency of therapy creates confusion about medications and results in sometimes not taking any actions when exacerbations arrive ([@b34-copd-3-371]).

A recent meta-analysis ([@b27-copd-3-371]) suggested that the objective severity of patients' disease conditions, and their awareness of this severity, can predict their adherence. Patients who are most severely ill with serious diseases may be at greatest risk for nonadherence to treatment. Depression further complicates therapy adherence among COPD patients. Depressed medical patients are 3 times more likely to be noncompliant with medication regimens, exercise, diet, health related behavior, vaccination, and appointments ([@b27-copd-3-371]). Patients with chronic illness are also likely to adhere to therapy if they trust the provider who prescribes the regimen, if there is evidence that the regimen is effective and does not cause distressing or frightening side effects that outweigh any therapeutic benefits, if the regimen does not significantly interfere with important daily activities, and if it does not have a significant impact on the individual's sense of identity ([@b90-copd-3-371]).

[Table 3](#t3-copd-3-371){ref-type="table"} shows beliefs, experiences, and health behaviors identified as strong predictors of low adherence to treatment in 276 patients with COPD. Each item is listed in order of statistical significance compared with subjects with high adherence ([@b34-copd-3-371]).

Patient satisfaction, patient preferences, and quality of life
==============================================================

Although patient's view of therapy is important as discussed above, relatively little has been investigated on the patient view of therapy involving monotherapy versus combination therapy and the use of a particular aerosol device. Most investigators assess the suitability of this form of therapy on response to lung function tests, reported improvements in exercise ability, and other indices of clinical efficacy mentioned above. Evaluation of issues such as well-being and symptom control, self-confidence, dependency, time and technical issues, as well as side effects and adherence provides a global assessment of quality of life. In a survey of 82 patients with chronic lung conditions on domiciliary nebulizer therapy, 98% of the patients receiving SVNs therapy reported favoring SVNs over pMDIs due to improved breathing, greater self-confidence, and less need to contact health care providers ([@b6-copd-3-371]).

The greatest change in quality of life have been reported when combination LABA -- ICS is used in patients with COPD (mean reduction of 3.0 units over 3 years) compared with a placebo group (a mean score of 48.4 at baseline, with an increase of 0.2 unit in the placebo group) ([@b12-copd-3-371]). The combination BUD -- FOR has a more significant reduction in the St George Respiratory Questionnaire (SGRQ) than the FLU -- SAL or placebo ([@b23-copd-3-371]; [@b1-copd-3-371]; [@b68-copd-3-371]).

Patients with COPD who are treated with an albuterol/ipratropium combination via SVN have statistically significant improvements from baseline in the SGRQ at 6 weeks. The concomitant use of SVN plus pMDI maintains significant improvement in total questionnaire score and symptom sub-scores at week 12 ([@b92-copd-3-371]).

Self-reported adherence
=======================

Although several techniques are used to measure adherence, the most commonly used is based on self-reports, which tend to overestimate adherence ([@b32-copd-3-371]). MARS is commonly used for self-reported adherence. A score of 25 indicates perfect adherence ([@b34-copd-3-371]).

Fifty percent of patients with COPD do not take their medications as prescribed ([@b45-copd-3-371]). Patients on regimens of up to 4 times daily who take less than 70% of the dose prescribed, and those on regimens of 5 times daily or over who take less than 60% of the dose prescribed, are defined as poorly adherent ([@b66-copd-3-371]; [@b7-copd-3-371]). Underuse, especially during periods of respiratory distress, is more common than overuse ([@b20-copd-3-371]; [@b45-copd-3-371]; [@b29-copd-3-371]).

While a qualitative study of compliance to medication and lifestyle modification in patients with COPD found that all patients except one reported good adherence to medication ([@b48-copd-3-371]), the overall reported adherence to treatment in COPD ranges from 41.3% ([@b93-copd-3-371]) to 57% ([@b29-copd-3-371]; [@b8-copd-3-371]). Factors such as fear of dyspnea and feelings of vulnerability appear to contribute to improvement in compliance. Ninety-three patients were asked how often they missed doses from their nebulizers and 66% stated that they never did (61% of the nonadherers and 72% of the adherers). Six percent reported missing doses only once a month, 10% admitted to missing doses once a week, and 7% (11% of the nonadherers and 3% of the adherers) stated that they missed a dose once a day ([@b8-copd-3-371]). Eleven percent of both adherers and nonadherers stated that they used the nebulizer only when they felt they needed to. Forgetting or deciding not to dose has been reported as the most common cause of poor adherence ([Figure 3](#f3-copd-3-371){ref-type="fig"}) ([@b29-copd-3-371]). Forgetting is reported by 51% of the patients, and 31% of the patients report consciously deciding not to dose.

Demographics
------------

An evaluation of predictors of patient adherence to long-term home nebulizer therapy in 985 patients with moderate to severe COPD enrolled in the Intermittent Positive Pressure Breathing (IPPB) Trial revealed that 49.4% of patients were nonadherent ([@b95-copd-3-371]). Good adherence was predicted by white race, married status, abstinence from cigarettes and alcohol, serum theophylline level \>9 pg/mL, more severe dyspnea, and reduced FEV~1~ (p \< 0.05). Subjects who were adherent to nebulizer therapy were older, better educated, had a stable lifestyle, were more likely to report that the therapy made them feel better, and were more likely to keep clinic appointments.

Refill adherence tends to be lower in younger patients, but lower in men than women (ratio of repeat prescriptions; 40/60 men/women) ([@b80-copd-3-371]; [@b75-copd-3-371]; [@b56-copd-3-371]). Men seem to have higher oversupplies (25%) than women (21%) and women slightly more undersupplies (22%) than men (20%) ([@b2-copd-3-371]). Older patients typically have more difficulty with the correct use of the inhaler than younger patients but there seems to be no difference in errors between men and women ([@b96-copd-3-371]).

A study on adherence to prescribed regimens of 74 patients with COPD reported that almost 54% of the patients (men = 27, women = 15) stopped their medications periodically over the previous 3 months, 47% (men = 26, women *=* 11) noted forgetting doses over the previous 3 months, and 44% (men = 23, women *=* 11) acknowledged being "careless" in taking their medications ([@b29-copd-3-371]). Thirty-nine patients (men = 25, women = 14) reported using more medication than was prescribed in times of distress. Thirty-eight percent of the men and 12% of the women used their inhaled medications with unsatisfactory technique.

Independent variables that are significantly associated with correct user of pMDI included sex and smoking status ([@b60-copd-3-371]). Men were more likely to use pMDI correctly: 77% of men used pMDI correctly, but only 33% of women used pMDI correctly. Non-smokers were more likely to have correct inhaler technique, whereas smokers were less likely. No significant association was observed between age, drinking, education level or living condition and correct pMDI technique.

Impact of teaching
==================

Although patients may read the instruction leaflet and receive face-to-face instruction, it is critical to evaluate whether or not patients are able to use the aerosol delivery device correctly. Patients' interest in reading written medical information such as how to use the inhaler may be influenced by several patient factors including disease state, health locus of control, coping style, health literacy levels, and occupation ([@b51-copd-3-371]). Since non-adherent patients have a tendency to report more confusion about medications than the highly adherent group, health care providers may need to spend more time especially with the elderly and those patients with polypharmacy ([@b34-copd-3-371]).

Even immediately after face-to-face instruction patients make mistakes. In a study comparing the Diskus and the Turbuhaler DPIs, 8% of patients made mistakes using the Diskus DPI and 26% using the Turbuhaler DPI right after reading the instruction leaflets ([@b101-copd-3-371]). Retention of instructions on appropriate use of the devices is progressively lost over time ([@b100-copd-3-371]). Inhalation technique was evaluated on average 6 months after they had received 3 different forms of instruction. Ninety-seven percent of the patients with small-group instruction demonstrated a good inhalation technique in comparison to 75% after video instruction, and 76% after personal instruction.

Using "ideal" technique as an outcome, the relative risk of all steps correct in teaching intervention groups compared with non-intervention groups has been around 2.08 (95% CI 1.59--2.78). The evidence shows that there is no difference between the pMDI and DPI. Any initial difference between the pMDI and DPI appears to be related partly to selection bias since appropriate inhaler technique achieved after a period of teaching has shown equivalent results for both pMDI and DPI ([@b10-copd-3-371]). The inhaler technique improves by counseling and the percentage of subjects performing steps correctly may double ([@b60-copd-3-371]).

Evaluation of the proportion of patients with COPD who are compliant with ICS use after education in a 1-year follow up showed no significant difference when compared with those who did not get the education ([@b33-copd-3-371]). However, the educated patients with COPD received less than half the amount of SABAs as rescue medications compared with the control group.

A sizeable number of primary care physicians treating patients with COPD are not aware of the GOLD guidelines and seem unclear about the role of inhaled medications at different stages of COPD (Foster et al 2007). Since primary care physicians provide care for a large percentage of patients with mild-to-moderate COPD, their diagnostic skills along with the knowledge and implementation of the guidelines is critical to the education, clinical outcome, and adherence to therapy of their patients with COPD.

Summary
=======

By considering only adherence to medications and the impact of teaching, we are falling short of recognizing the critical role played by other forms of nonpharmacologic treatment such as smoking cessation, alternative medicine, diet, exercise, and psychotherapy and their impact at different stages of COPD and/or in patients of different cultures. All aspects of therapy and the impact each one has on the currently reported poor adherence to COPD therapy need to be evaluated. Adherence to therapy at different stages of COPD is important since the extent of impairment influences perceived symptoms, medication algorithms, ability to adhere with therapy and perceived benefit of medication. This distinction could have significant implications in important outcomes discussed earlier. However, we could not find reports that measured the impact of specific stages of COPD on adherence to medication.

Therapies for COPD can be effective and improve outcomes only if well prescribed and if they are used by patients. The most common type of nonadherence to therapy is underuse. More than half of patients with COPD report missing or skipping doses of their medication ([@b34-copd-3-371]; [@b40-copd-3-371]; [@b53-copd-3-371], [@b54-copd-3-371], [@b52-copd-3-371]). Forgetting to dose is the most common situational factor that explains poor adherence ([@b29-copd-3-371]; [@b8-copd-3-371]). The decision not to dose due to feeling good is concerning. During respiratory distress, patients often report using more than the prescribed amount of medications ([@b8-copd-3-371]; [@b29-copd-3-371]).

Adherence also depends on clinical efficacy of the prescribed medications. In patients with COPD, a LABA -- ICS combination produces a statistically significant and clinically relevant benefit without substantial differences between aerosol delivery systems. The superiority of combination inhalers should be viewed against the increased risk of side effects, particularly pneumonia ([@b12-copd-3-371]). The class of medication appears to be uniformly associated with adherence. There is a noticeable pattern for patients to report better adherence with corticosteroids and antibiotics than with theophylline, inhaled beta agonists, and inhaled anticholinergic agents. Unfortunately, the underlying causes of these differences have not been determined. The complexity of medication regimens frequently prescribed for patients with COPD adversely affect adherence to treatment ([@b53-copd-3-371]).

When selecting an aerosol delivery device for patients with COPD, the following aspects should be considered to improve adherence to therapy: device -- medication availability; clinical setting; patient age and the ability to use the selected device correctly; device use with multiple medications; cost and reimbursement; medication administration time; convenience in both outpatient and inpatient settings; and physician and patient preference. Almost all popular inhalers seem to be acceptable when overall preference is assessed, but most patients choose their devices based on ease of use in general and during an exacerbation, the feel of the device in the hand, ease of opening the cap, and the ability to take the medication quickly in case of an impending exacerbation ([@b97-copd-3-371]). Patients using combined SVN therapy morning and night with midday inhaler use seem to have the most statistically significant improvements in quality of life. This concomitant regimen may provide the additional symptom relief offered by a SVN with the convenience of an inhaler when patients are away from home ([@b4-copd-3-371]; [@b92-copd-3-371]). Since most patients consider the pMDI to be more acceptable and the SVN to be more effective, these preferences should be taken into consideration when prescribing a maintenance aerosol inhalation treatment.

There is significant evidence showing that nearly 100% of patients with COPD make errors on the steps necessary to adequately use inhalers and many patients with COPD display a technique that possibly delivers an inadequate dose of medication ([@b44-copd-3-371]; [@b77-copd-3-371]; [@b60-copd-3-371]). However, the number of instructions needed to obtain a perfect inhalation technique and the type of instruction that sustains patient's mastery over time has not been clearly defined. Regular instructions, supervision, and check up of inhalation technique are the responsibility of the treating physician. Under real-life conditions, inappropriate use of inhalers is common and strongly correlates with a lack of instruction by the caregiver (Sestini et al 2007). The benefit of providing mere information and well-written instructions without "hands-on" demonstration has been thought as not providing information at all (Sestini et al 2007). Health professionals need to assess the utility of written medical information in the tailoring of patient education to meet patient needs.

Although insufficient funds have been reported of limited importance as a factor limiting adherence to a medication regimen ([@b29-copd-3-371]), pharmacoeconomics is considered a relevant issue in clinical practice ([@b78-copd-3-371]). If reimbursement is considered, SVNs may be more cost effective and may explain why an increasing number of patients request a change to SVN ([@b77-copd-3-371]). Cost of the aerosol delivery device is at least as important as or perhaps more important than cost of the medication for adherence to therapy.

Patients' acceptance and knowledge of the disease process as well as the recommended treatment, faith in the treatment, effective patient -- clinician interaction are all critical for optimal medication adherence in patients with COPD. Psychological factors such as depression in patients with COPD have not been extensively studied. Depression may cause a patient to neglect themselves and their treatment and influence respiratory symptoms by being a cause of nonadherence. It is very possible that the increased sense of impairment in quality of life is associated with poor adherence to treatment ([@b28-copd-3-371], [@b27-copd-3-371]). Although some studies have revealed an association between demographic variables such as gender, age, and race to adherence, studies with larger samples are needed ([@b2-copd-3-371]; [@b60-copd-3-371]).

There is a need for further research to determine how, when, and where in the course of COPD patients need to be educated on all aspects of their disease to improve adherence to their prescribed therapeutic regimen. Physicians' role on adherence should be thoroughly investigated to establish strategies that improve adherence since current evidence has been focused mostly on the patient level. The impact of poor implementation of existing guidelines for COPD by physicians on patients' adherence to treatment has been poorly investigated. Only about 45% of primary care physicians taking care of patients with COPD are aware of major COPD guidelines. However 75% of them do not use them to prescribe therapy for their patients with COPD (Foster et al 2007). The optimal use of recent advances in medicine depends heavily on developing effective communication between health care professionals and their patients ([@b64-copd-3-371]). Strong education initiatives enable patients to respond effectively to the prescribed therapeutic regimens. A collaborative self-management approach recognizes the patient's role in making his or her own health decisions and the physician's role as an educator and facilitator of the patient's health decisions ([@b5-copd-3-371]). Health care practitioners should recognize the complexity of prescribed treatments and routinely utilize strategies to promote patient adherence.

Improving efforts by the physicians to increase education about the illness and the treatment options along with the inclusion of psychological treatments in management plans is critical to improving adherence to therapy in patients with COPD who find every day a challenge to adhere to their therapeutic regimen.
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###### 

Most common adverse effects with combination therapy

  Adverse effect    Nr of studies   Nr of patients   OR; 95% CI
  ----------------- --------------- ---------------- -----------------------------
  Pneumonia         7               5229             OR 1.80; 95% CI 1.48--2.18
  Candidiasis       6               1958             OR 5.73; 95% CI 3.07--10.67
  Hoarseness        2               585              OR 8.79; 95% CI 1.11--69.62
  Nasopharyngitis   2               3535             OR 1.28; 95% CI 1.05--1.56
  URTI              5               4963             OR 1.23; 95% CI 1.04--1.47

**Abbreviations:** CI, confidence interval; OR, odds ratio; URTI, upper respiratory tract infections.

###### 

Steps for correct use of the inhaler

  Steps for correct use of the inhaler
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Remove coverShake inhaler wellHold inhaler uprightExhale gentlyPlace mouthpieceActuate canister once at the beginning of inhalationInhale slowly and deeplyHold breath at least 10 secondsBreath out slowly

###### 

Beliefs, experiences, and health behaviors identified predictors of low adherence to treatment in 276 patients with COPD. The highlighted variables explained almost 20% variance in nonadherence in this study ([@b34-copd-3-371])

  ----------------------------------------------------------------------------------
  **Beliefs**
  I do not have sufficient understanding about my illness
  My doctors are not very knowledgeable
  Natural remedies are safer than medicines
  My doctors have limited management options to offer me
  I do not have sufficient understanding about the options for managing my illness
  The management of my illness is a mystery for me
  **Experiences**
  It is unpleasant to use some of my medications
  It is physically difficult to handle some of my medications
  I am not satisfied with the information my doctors share with me
  My doctors are not compassionate
  ***My doctors don't spend adequate time with me***
  **Behaviors**
  ***I get confused about my medications***
  ***I vary my recommended management based on how I am feeling***
  I put up with my medical problems before taking any action
  I make changes in the recommended management to suit my lifestyle
  ----------------------------------------------------------------------------------
